Kinetics of testosterone metabolism in normal postmenopausal women and women with breast cancer. 1978

C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark

The constant infusion and single injection techniques were utilized to study the kinetics of 3H-testosterone (T) metabolism in posmenopausal women with and without breast cancer. The metabolic clearance rates (mean +/- SEM) for normal postmenopausal women were 578 +/- 82 and 644 +/- 128 1/24 has obtained by the constant infusion and single injection techniques, respectively. The corresponding results for the women with breast cancer (patients) are 644 +/- 25 and 617 +/- 106 1/24 h. The single injection technique yielded values for rate constants (units) and volumes of distribution (1); K1 = 37.5 +/- 1.6 for the normals and 34.5 +/- 1.9 for the patients, K = 76.6 +/- 5.1 for the normals and 71.1 +/- 1.6 for the patients, V1 = 7.9 +/- 2.2 for the normals and 8.7 +/- 1.4 for the patients and V2 = 7.0 +/- 1.5 for the normals and 6.4 +/- 1.2 for the patients. The constant infusion technique yielded values for the conversion ratios for the transformation of T to several products; 4-androstene-3,17-dione/T of 0.02 +/- 0.003 for normals and 0.03 +/- 0.002 for patients, 5alpha-dihydrotestosterone/T of 0.02 +/- 0.002 for normals and 0.03 +/- 0.002 for patients, estrone/T of 0.04 +/- 0.01 for normals and 0.04 +/- 0.01 for patients, estradiol-17beta/T of 0.02 +/- 0.005 for normals and 0.03 +/- 0.005 for patients and estrone sulfate/T of 0.16 +/- 0.02 for normals and 0.24 +/- 0.06 for patients. The T plasma concentrations and production rates were similar for the two groups of subjects. Hence there were no significant differences between the normals and the patients for all the kinetic parameters. It was determined that all the estradiol being produced in postmenopausal women could be coming from circulating T.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004970 Estrone An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women. Folliculin (Hormone),Estrone, (+-)-Isomer,Estrone, (8 alpha)-Isomer,Estrone, (9 beta)-Isomer,Estrovarin,Kestrone,Unigen,Wehgen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
January 1985, Clinical and investigative medicine. Medecine clinique et experimentale,
C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
November 1986, European journal of cancer & clinical oncology,
C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
October 1968, European journal of cancer,
C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
February 2012, Journal of the National Cancer Institute,
C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
July 2006, Archives of internal medicine,
C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
December 2014, The Journal of clinical endocrinology and metabolism,
C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
March 2008, Maturitas,
C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
November 2009, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
December 2004, Maturitas,
C E Bird, and W Finnis, and K Boroomand, and J Murphy, and A F Clark
July 2011, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Copied contents to your clipboard!